Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors
Status:
RECRUITING
Trial end date:
2027-09-14
Target enrollment:
Participant gender:
Summary
The purpose of the study is to find some biomarkers to predict the the adverse events of Immune Checkpoint Inhibitors monotherapy or plus platinum based chemotherapy in lung cancer.